Abivax (ABVX) news
Recent news
Eqs-news: Abivax to present data on Obefazimod at United European Gastroenterology (UEG) week 2026
Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) announced that it will present data on its lead drug candidate, obefazimod, at the United European Gastroenterology (UEG) Week 2026, scheduled for October 2026 . The presentation will include clinical findings from its ongoing trials…
AInvest Wire · Sep 30, 2026ABivax SA: Wedbush cuts target price to $118 from $140
Wedbush analyst has revised its price target for Abivax SA (ABVX), lowering it to $118 from the previous $140, according to the latest update. The adjustment reflects a reassessment of the company’s near-term outlook and market conditions. Despite the reduced target, the firm maintains a positive…
AInvest Wire · Sep 22, 2026ABivax SA: Truist Securities cuts target price to $151 from $155
Truist Securities has adjusted its price target for Abivax SA (NASDAQ: ABVX), reducing it to $151 from the previous $155, while maintaining a "Buy" rating . The move follows ongoing analyst reviews of the company’s clinical and financial developments, including recent updates on its lead drug…
AInvest Wire · Sep 22, 2026ABIVAX H1 net income EUR -165.9 million
Abivax S.A. reported a net loss of EUR -165.9 million for the first half of 2025, reflecting continued financial pressure as a pre-revenue clinical-stage company. The operating loss for the period increased by EUR 13.7 million to EUR 93.7 million, driven primarily by higher R&D expenses, which rose…
AInvest Wire · Sep 21, 2026ABivax presents business updates and first half 2026 financial results
AInvest Wire · Sep 21, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.